Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

 

We lease our corporate, laboratory and other facilities under multiple operating leases at the EPFL Innovation Park in Ecublens, near Lausanne, Canton of Vaud, Switzerland. Our lease agreements have no termination clauses longer than a 12-month contractual notice period. Rental expense for the years ended December 31, 2018, 2017 and 2016 was CHF 0.8 million, 0.5 million and CHF 0.4 million, respectively. As of December 31, 2018, rental contracts for CHF 0.8 million were committed for 2019.

 

 

As of

December 31,

in CHF thousands

2018 

 

2017 

Within one year 19,880   9,686
Between one and three years 6,995   2,546
Between three and five years 5,009   140
More than five years 1,190  
Total 33,074   12,372

 

18.Earnings per share

 

   

For the Years Ended

December 31,

in CHF thousands except for share and per share data   2018   2017   2016
Net income / (loss) attributable to owners of the Company    (50,951)   (26,411)   (7,096)
Earnings per share (EPS):            
Basic and diluted, income / (loss) for the period attributable to equity holders    (0.82)   (0.46)   (0.14)
Weighted-average number of shares used to compute EPS basic and diluted    61,838,228   57,084,295   50,096,859

 

Since we have a loss for all periods presented, basic net loss per share is the same as diluted net loss per share. We have excluded from our calculation of diluted loss per share all potentially dilutive in-the-money (i) share options and (ii) restricted share awards as the inclusion of these awards would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: 

 

   

As of

December 31,

    2018   2017   2016
Share options issued and outstanding (in-the-money)    1,472,589   1,341,042   1,687,900
Restricted share awards subject to future vesting    109,041   122,014   — 
Total   1,581,630   1,463,056   1,687,900

 

19.Financial instruments and risk management

 

The Company’s activities expose it to the following financial risks: market risk (foreign exchange and interest rate risk), credit risk and liquidity risk. The Company’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Company’s financial performance.

 

 F-35


© AC Immune 2015